|
|
Article: Gilead's Hepsera Approved To Treat Chronic Hepatitis B.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Less than two months after an advisory panel unanimously recommended approval of Gilead Sciences Inc.'s Hepsera (adefovir dipivoxil) for chronic hepatitis B, the FDA has given its expected nod and the company plans to ship the drug this week - with a price tag that was higher than some analysts had forecast.
"We've spoken to several advocates and they think the price is fair," said Erin Edgley, public affairs specialist with Foster City, Calif.-based Gilead, adding that physicians already have begun writing prescriptions and the company has set up an assistance program for patients not reimbursed by insurance for the drug.
...